Plasma ctDNA Genotyping Can Accelerate Time to Treatment for NSCLC
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, July 28, 2023 -- For patients with suspected advanced non-small cell lung cancer (NSCLC), plasma circulating tumor (ct)DNA genotyping before tissue diagnosis is associated with accelerated time to treatment, according to a study published online July 25 in JAMA Network Open.
Miguel García-Pardo, M.D., from the Princess Margaret Cancer Centre at the University Health Network in Toronto, and colleagues conducted a single-group nonrandomized clinical trial among 150 patients. Eligible patients were referred for investigation and diagnosis of lung cancer if they had radiologic evidence of advanced lung cancer prior to a tissue diagnosis. Before lung cancer diagnosis, patients underwent plasma ctDNA testing with a next-generation sequencing (NGS) assay. The primary end point was time from referral to treatment initiation among patients with advanced nonsquamous NSCLC using ctDNA testing before diagnosis (Accelerating Lung Cancer Diagnosis Through Liquid Biopsy [ACCELERATE] cohort) compared with a reference cohort using standard tissue genotyping after tissue diagnosis.
Ninety of the 150 patients enrolled had advanced nonsquamous NSCLC. The researchers found that the median time to treatment was 39 and 62 days for the ACCELERATE and reference cohorts, respectively. From sample collection to genotyping results, the median turnaround time was seven days for plasma and 23 days for tissue NGS among the ACCELERATE cohort. Of the 90 patients with nonsquamous NSCLC, 23 and 12 percent started targeted therapy before tissue NGS results were available and had actionable alterations identified only through plasma testing, respectively.
"The effect of this approach on clinically meaningful outcomes, such as quality of life, survival, and cost-effectiveness, still needs to be demonstrated," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
Perioperative Nivolumab Tops Chemo for Survival in Resectable Lung Cancer
FRIDAY, May 17, 2024 -- For patients with resectable non-small cell lung cancer (NSCLC), perioperative treatment with nivolumab results in significantly longer event-free...
AACR Delivers Report on Disparities in Cancer Progress
WEDNESDAY, May 15, 2024 -- In its biennial Cancer Disparities Progress Report published today, the American Association for Cancer Research presents the latest statistics on...
Alecensa Approved as First and Only ALK Inhibitor for Non-Small Cell Lung Cancer
MONDAY, April 22, 2024 -- The U.S. Food and Drug Administration has approved Alecensa (alectinib) as adjuvant treatment following tumor resection in patients with anaplastic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.